June 16, 2020 : DCMS #506

TOP STORIES — Diabetes News and Research

A New Diabetes Drug Class

Patient-Specific Factors Affect Metformin Adherence

Comparing Long-Term HbA1C Variability with All-Cause Mortality in the ACCORD Trial

MOST POPULAR ARTICLES OF THE MONTH

#1 Why CGM?

#2 Did You Know? Metformin, along with dozens of drugs, may have promise against COVID-19 

#3 5 Key Exercises for People with Diabetes

We have spent a lot of time talking about TIR (Time in Range) for diabetes patients, but most of it is focused on type 1 patients. There is even more info on the long-term benefits of increased TIR being presented at this week’s ADA Virtual Scientific sessions.

But what about this idea for patients with type 2 diabetes? Can they benefit from less variability from month to month, and from office visit to office visit? This week our intern, Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy, looked back at the ACCORD trial and found there is a direct connection between Long Term A1c Stability and better outcomes.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Abbott announced on June 15th that the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes. 

Imeglimin, a new, first-in-class blood-glucose-lowering agent, proves to be safe and efficient as monotherapy and adjunctive therapy to lower A1C in patients with type 2 diabetes. 

A large UK study investigates which patients may be likely to discontinue metformin therapy. 

Study shows that visit-to-visit HbA1C variability can have significant effects on the prognosis for patients living with diabetes.